IL304467A - Pharmaceutical compositions for the treatment of breast cancer and methods of using them - Google Patents

Pharmaceutical compositions for the treatment of breast cancer and methods of using them

Info

Publication number
IL304467A
IL304467A IL304467A IL30446723A IL304467A IL 304467 A IL304467 A IL 304467A IL 304467 A IL304467 A IL 304467A IL 30446723 A IL30446723 A IL 30446723A IL 304467 A IL304467 A IL 304467A
Authority
IL
Israel
Prior art keywords
methods
pharmaceutical compositions
breast cancers
treating breast
treating
Prior art date
Application number
IL304467A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US20210228529A1/en
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of IL304467A publication Critical patent/IL304467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL304467A 2021-01-15 2023-07-13 Pharmaceutical compositions for the treatment of breast cancer and methods of using them IL304467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/151,108 US20210228529A1 (en) 2012-07-13 2021-01-15 Pharmaceutical compositions for treating breast cancers and methods of uses thereof
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (1)

Publication Number Publication Date
IL304467A true IL304467A (en) 2023-09-01

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304467A IL304467A (en) 2021-01-15 2023-07-13 Pharmaceutical compositions for the treatment of breast cancer and methods of using them

Country Status (10)

Country Link
EP (1) EP4277613A4 (https=)
JP (1) JP2024503718A (https=)
KR (1) KR20230163362A (https=)
CN (1) CN116981451A (https=)
AU (1) AU2022208712A1 (https=)
BR (1) BR112023014247A2 (https=)
CA (1) CA3205212A1 (https=)
IL (1) IL304467A (https=)
MX (1) MX2023008375A (https=)
WO (1) WO2022155543A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (zh) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 丙酰胺类雄激素受体拮抗剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
LT2872482T (lt) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) * 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
MX389702B (es) * 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders

Also Published As

Publication number Publication date
BR112023014247A2 (pt) 2023-10-03
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31
MX2023008375A (es) 2023-10-05
EP4277613A1 (en) 2023-11-22
WO2022155543A1 (en) 2022-07-21
CA3205212A1 (en) 2022-07-21
AU2022208712A9 (en) 2024-09-19
JP2024503718A (ja) 2024-01-26
EP4277613A4 (en) 2024-11-20
KR20230163362A (ko) 2023-11-30

Similar Documents

Publication Publication Date Title
IL300067A (en) Preparations and methods for the treatment of cancers
IL304467A (en) Pharmaceutical compositions for the treatment of breast cancer and methods of using them
SI4181920T1 (sl) Inhibitor kat6 in kombinacije za zdravljenje raka dojke
FI4126066T3 (fi) Koostumuksia ja menetelmiä lihasdystrofian hoitoon
IL308766A (en) Compositions and methods for treating prostate cancer
GB202018015D0 (en) Composition and methods for the treatment of intestinal cancer
PL4058474T3 (pl) Kompozycje i sposoby leczenia nowotworów egfr-dodatnich
IL315800A (en) Preparations and methods for the treatment of cancer
IL276203A (en) Compounds and methods for treating cancer
IL288787A (en) Methods and preparations to improve results in cancer patients
IL299039A (en) Methods and preparations for the treatment of triple-negative breast cancer
IL287538A (en) Preparations and methods for the treatment of cancer
IL309120A (en) Methods and compositions for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
IL308530A (en) Preparations and methods for treating lung cancer
GB202107994D0 (en) Treatment of cancer
EP4132657A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANTICANCER-RESISTANT CANCER
EP3999065C0 (en) THERAPEUTIC COMPOSITIONS AND PROCESSES COMPRISING IDELALISIB AND DEFACTINIB FOR THE TREATMENT OF BREAST CANCER
IL312846A (en) Methods and preparations for the treatment of cancer
IL277313A (en) Sposin C Pharmaceuticals and Cancer Treatment Methods
IL304591A (en) Preparations and methods for the treatment of skin cancers
GB202215066D0 (en) Bifidobacterium and compositions thereof for breast cancer treatment
IL316047A (en) Preparations and methods for the treatment of cancer
IL308642A (en) Diagnostic methods and compositions for the treatment of cancer
IL272390A (en) Cancer treatment methods